<div id="pf33" class="pf w21 h0" data-page-no="33"><div class="pc pc33 w21 h0"><img class="bi x13 y199 w23 h31" alt="" src="data:image/png;base64,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"/><div class="t m0 x13 h2d y19a ffe fse fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x14 h32 y19b ffe fsf fc0 sc0 ls1 ws1">®</div><div class="t m0 x61 h2d y19a ffe fse fc0 sc0 ls1 ws1">_comp_rev<span class="_ _6"></span>_V7_VP </div><div class="t m0 x13 h27 y1d8 ffe fsa fc0 sc0 ls1 ws1">como <span class="_ _6b"></span>erupção<span class="_ _0"></span> <span class="_ _6b"></span>cutânea, <span class="_ _6b"></span>a<span class="_ _0"></span>ngioedema <span class="_ _6b"></span>(inchaço <span class="_ _6a"></span>em <span class="_ _6b"></span>região <span class="_ _6b"></span>s<span class="_ _0"></span>ubcutânea <span class="_ _6b"></span>o<span class="_ _0"></span>u <span class="_ _6b"></span>em <span class="_ _6a"></span>mucosas, <span class="_ _6b"></span>geral<span class="_ _0"></span>mente <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _6b"></span>origem <span class="_ _6b"></span>a<span class="_ _0"></span>lérgica) <span class="_ _6a"></span>ou<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1d9 ffe fsa fc0 sc0 ls1 ws1">reações he<span class="_ _0"></span>matológicas (do<span class="_ _0"></span> sangue) co<span class="_ _0"></span>mo trombocitop<span class="_ _0"></span>enia (di<span class="_ _0"></span>minuição no <span class="_ _0"></span>número de <span class="_ _6b"></span>plaquetas sanguíneas) <span class="_ _0"></span>e <span class="_ _0"></span>neutropenia </div><div class="t m0 x13 h27 y1db ffe fsa fc0 sc0 ls1 ws1">(diminuição do número d<span class="_ _0"></span>e neutró<span class="_ _0"></span>filos no sangue).<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1dc ffe fsa fc0 sc0 ls1 ws1">Pacientes <span class="_ _6b"></span>q<span class="_ _0"></span>ue <span class="_ _6b"></span>desenvolvera<span class="_ _0"></span>m <span class="_ _6b"></span>reaçõ<span class="_ _0"></span>es <span class="_ _6b"></span>alérgicas <span class="_ _6b"></span>e/o<span class="_ _0"></span>u <span class="_ _6b"></span>hemat<span class="_ _0"></span>ológicas <span class="_ _6b"></span>anterior<span class="_ _0"></span>mente <span class="_ _6b"></span>a <span class="_ _6a"></span>alguma <span class="_ _6b"></span>tienopiridina <span class="_ _6a"></span>pode<span class="_ _10"></span>m <span class="_ _6b"></span>ter <span class="_ _6a"></span>um </div><div class="t m0 x13 h27 y20c ffe fsa fc0 sc0 ls1 ws1">maior <span class="_ _0"></span>r<span class="_ _0"></span>isco <span class="_ _10"></span>de <span class="_ _10"></span>desenvolvimento <span class="_ _10"></span>da <span class="_ _10"></span>mesma <span class="_ _0"></span>o<span class="_ _0"></span>u <span class="_ _0"></span>no<span class="_ _0"></span>va <span class="_ _0"></span>reaçã<span class="_ _0"></span>o <span class="_ _10"></span>a <span class="_ _0"></span>o<span class="_ _0"></span>utra <span class="_ _0"></span>tienop<span class="_ _0"></span>iridina. <span class="_ _6b"></span>Aco<span class="_ _0"></span>nselha-se <span class="_ _10"></span>monitoramento <span class="_ _10"></span>do<span class="_ _0"></span>s <span class="_ _0"></span>sinais </div><div class="t m0 x13 h27 y1dd ffe fsa fc0 sc0 ls1 ws1">de sensibilidade cruzada <span class="_ _0"></span>em pac<span class="_ _0"></span>ientes com alergia conhecid<span class="_ _0"></span>a às tienopiridinas<span class="_ _0"></span>.<span class="ls12">  </span> </div><div class="t m0 x13 h24 y1df fff fsa fc0 sc0 ls1 ws1">Populações Especiais <span class="_ _0"></span> </div><div class="t m0 x13 h24 y1e0 fff fsa fc0 sc0 ls1 ws1">Pacientes <span class="_ _6a"></span>co<span class="_ _0"></span>m <span class="_ _6a"></span>insuficiência <span class="_ _6a"></span>nos <span class="_ _6a"></span>rins:<span class="ffe"> <span class="_ _6a"></span>a <span class="_ _6a"></span>exper<span class="_ _0"></span>iência <span class="_ _6a"></span>com <span class="_ _6a"></span>clopidogrel <span class="_ _6a"></span>é <span class="_ _6a"></span>limitada <span class="_ _6a"></span>em <span class="_ _6a"></span>pacientes <span class="_ _6a"></span>co<span class="_ _0"></span>m <span class="_ _6b"></span>i<span class="_ _0"></span>nsuficiência <span class="_ _6a"></span>renal </span></div><div class="t m0 x13 h27 y1e1 ffe fsa fc0 sc0 ls1 ws1">severa (redução <span class="_ _0"></span>severa da função <span class="_ _0"></span>dos rins).  Portanto, <span class="_ _0"></span>clopidogrel deve ser usado co<span class="_ _0"></span>m cautela nestes p<span class="_ _0"></span>acientes.   <span class="_ _10"></span> </div><div class="t m0 x13 h24 y1e3 fff fsa fc0 sc0 ls1 ws1">Pacientes <span class="_ _6a"></span>com <span class="_ _6b"></span>insufic<span class="_ _0"></span>iência <span class="_ _6a"></span>no <span class="_ _6b"></span>fíg<span class="_ _0"></span>ado: <span class="_ _6a"></span><span class="ffe">a <span class="_ _6b"></span>exper<span class="_ _0"></span>iência <span class="_ _6b"></span>é <span class="_ _6a"></span>limitada <span class="_ _6b"></span>e<span class="_ _0"></span>m <span class="_ _6b"></span>paciente<span class="_ _0"></span>s <span class="_ _6b"></span>co<span class="_ _0"></span>m <span class="_ _6a"></span>insuficiência <span class="_ _6a"></span>no <span class="_ _6a"></span>fígado <span class="_ _6b"></span>severa <span class="_ _6a"></span>que </span></div><div class="t m0 x13 h27 y1e4 ffe fsa fc0 sc0 ls1 ws1">possam <span class="_ _6b"></span>apresentar <span class="_ _6b"></span>diátese <span class="_ _6a"></span>hemorrágica <span class="_ _6b"></span>(sangramentos <span class="_ _6b"></span>ca<span class="_ _0"></span>usados <span class="_ _6b"></span>po<span class="_ _0"></span>r <span class="_ _6b"></span>uma <span class="_ _6b"></span>falha <span class="_ _6b"></span>na <span class="_ _6b"></span>coagulação<span class="_ _0"></span> <span class="_ _6b"></span>ou <span class="_ _6b"></span>na <span class="_ _6b"></span>estrutura <span class="_ _6b"></span>d<span class="_ _0"></span>os <span class="_ _6b"></span>vasos </div><div class="t m0 x13 h27 y1e5 ffe fsa fc0 sc0 ls1 ws1">sanguíneos). Clopid<span class="_ _0"></span>ogrel deve ser utilizado co<span class="_ _0"></span>m cautela nestes pac<span class="_ _0"></span>ientes.  <span class="_ _0"></span> </div><div class="t m0 x13 h24 y1e7 fff fsa fc0 sc0 ls1 ws1">Efeitos na capacida<span class="_ _0"></span>de de conduzir/operar <span class="_ _0"></span>máquinas<span class="_ _0"></span><span class="ffe">  </span></div><div class="t m0 x13 h27 y1e8 ffe fsa fc0 sc0 ls1 ws1">Não <span class="_ _6b"></span>foi <span class="_ _6b"></span>o<span class="_ _0"></span>bservada <span class="_ _6b"></span>qualquer <span class="_ _6a"></span>alteração <span class="_ _6b"></span>na <span class="_ _6b"></span>capacidad<span class="_ _0"></span>e <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _6b"></span>condução <span class="_ _6b"></span>ou <span class="_ _6b"></span>dese<span class="_ _0"></span>mpenho <span class="_ _6b"></span>psicométrico <span class="_ _6a"></span>(avaliação <span class="_ _6b"></span>de <span class="_ _6b"></span>processos </div><div class="t m0 x13 h27 y1e9 ffe fsa fc0 sc0 ls1 ws1">mentais) dos pacientes apó<span class="_ _0"></span>s administração d<span class="_ _0"></span>e <span class="_ _0"></span>Plaq</div><div class="t m0 x70 h37 y20d ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x71 h27 y1e9 ffe fsa fc0 sc0 ls1 ws1"> (bissulfato de clop<span class="_ _0"></span>idogrel)<span class="ls12">.  </span> </div><div class="t m0 x13 h24 y1eb fff fsa fc0 sc0 ls1 ws1">Gravidez e a<span class="_ _0"></span>mamentação   </div><div class="t m0 x13 h27 y1ec ffe fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x61 h37 y20e ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6c h27 y1ec ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _7"></span>(bissulfato <span class="_ _6"></span>de <span class="_ _7"></span>clopidogrel<span class="_ _0"></span>) <span class="_ _7"></span>não <span class="_ _6"></span>deve <span class="_ _7"></span>ser <span class="_ _6"></span>usado <span class="_ _7"></span>durante a <span class="_ _7"></span>gravidez <span class="_ _7"></span>a <span class="_ _6"></span>menos <span class="_ _7"></span>que <span class="_ _6"></span>na <span class="_ _7"></span>opinião <span class="_ _6"></span>do <span class="_ _7"></span>seu <span class="_ _6"></span>médico, <span class="_ _7"></span>seja <span class="_ _6"></span>evidente </div><div class="t m0 x13 h27 y1ed ffe fsa fc0 sc0 ls1 ws1">a sua necessidade.   <span class="_ _0"></span> </div><div class="t m0 x13 h24 y1ef fff fsa fc0 sc0 ls1 ws1">Este medica<span class="_ _0"></span>mento não deve ser utilizado<span class="_ _0"></span> por mulheres grá<span class="_ _0"></span>vidas sem orientaçã<span class="_ _0"></span>o médica<span class="_ _0"></span>,<span class="_ _0"></span> ou do cirurgião<span class="_ _0"></span>-dentista<span class="ls12">.   </span></div><div class="t m0 x13 h27 y1f1 ffe fsa fc0 sc0 ls1 ws1">Visto que muitos <span class="_ _0"></span>medicamentos são <span class="_ _0"></span>excretado<span class="_ _0"></span>s no leite materno, <span class="_ _0"></span>e devido ao r<span class="_ _0"></span>isco potencial de reações a<span class="_ _0"></span>dversas sérias no </div><div class="t m0 x13 h27 y20f ffe fsa fc0 sc0 ls1 ws1">lactente, <span class="_ _6a"></span>seu <span class="_ _6b"></span>médico<span class="_ _0"></span> <span class="_ _6a"></span>decidirá <span class="_ _6b"></span>entre <span class="_ _6a"></span>interromper <span class="_ _6a"></span>a <span class="_ _6a"></span>am<span class="_ _6"></span>amentaç<span class="_ _0"></span>ão <span class="_ _6a"></span>ou <span class="_ _6b"></span>descontinuar <span class="_ _6a"></span>o <span class="_ _6a"></span>tratamento <span class="_ _6a"></span>com <span class="_ _6a"></span>P<span class="_ _0"></span>laq</div><div class="t m0 x72 h37 y210 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x73 h27 y20f ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _6a"></span>(bissulfato <span class="_ _6a"></span>de </div><div class="t m0 x13 h27 y1f2 ffe fsa fc0 sc0 ls1 ws1">clopidogrel<span class="_ _0"></span>)<span class="ls12">.  </span> </div><div class="t m0 x13 h24 y1f4 fff fsa fc0 sc0 ls1 ws1">INTERAÇÕES M<span class="_ _0"></span>EDICAMENTO<span class="_ _0"></span>SAS  </div><div class="t m0 x13 h38 y211 ff14 fsa fc0 sc0 ls1 ws1">Medicamentos associados com <span class="_ _6"></span>o risco de <span class="_ _6"></span>hemorragia (sangra<span class="_ _0"></span>m<span class="_ _6"></span>ento)<span class="_ _0"></span><span class="ff13 ls13">: <span class="ls1">existe um risco <span class="_ _6"></span>aumentado de hemorragia devido </span></span></div><div class="t m0 x13 h38 y212 ff13 fsa fc0 sc0 ls1 ws1">ao <span class="_ _6b"></span>efeito <span class="_ _10"></span>po<span class="_ _0"></span>tencial <span class="_ _10"></span>aditivo. <span class="_ _6a"></span>A <span class="_ _10"></span>ad<span class="_ _0"></span>ministração <span class="_ _10"></span>conco<span class="_ _0"></span>mitante <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _6b"></span>medicamentos <span class="_ _10"></span>a<span class="_ _0"></span>ssociados <span class="_ _6b"></span>ao <span class="_ _6b"></span>risco <span class="_ _6b"></span>de <span class="_ _6b"></span>hemorragia <span class="_ _10"></span>de<span class="_ _0"></span>ve <span class="_ _10"></span>se<span class="_ _0"></span>r </div><div class="t m0 x13 h38 y213 ff13 fsa fc0 sc0 ls1 ws1">feita com precaução.<span class="_ _0"></span>  </div><div class="t m0 x13 h24 y214 fff fsa fc0 sc0 ls1 ws1">Trombolíticos <span class="_ _40"> </span>(medica<span class="_ _0"></span>mentos <span class="_ _6c"></span>usados <span class="_ _40"> </span>para <span class="_ _6c"></span>inibir <span class="_ _40"> </span>a <span class="_ _6c"></span>coa<span class="_ _0"></span>gulação <span class="_ _40"> </span>sanguínea):<span class="_ _0"></span><span class="ffe"> <span class="_ _40"> </span>a <span class="_ _6c"></span>segurança <span class="_ _6c"></span>do<span class="_ _0"></span> <span class="_ _6c"></span>uso <span class="_ _6c"></span>e<span class="_ _0"></span>m <span class="_ _6a"></span>as<span class="_ _0"></span>sociação <span class="_ _6c"> </span>d<span class="_ _0"></span>e </span></div><div class="t m0 x13 h27 y215 ffe fsa fc0 sc0 ls1 ws1">clopidogrel, <span class="_ _6d"> </span>trombolíticos <span class="_ _6d"> </span>e  h<span class="_ _6"></span>eparina <span class="_ _6d"> </span>foi <span class="_ _6d"> </span>estudada <span class="_ _6d"> </span>e<span class="_ _0"></span>m <span class="_ _40"> </span>pacientes <span class="_ _6d"> </span>co<span class="_ _0"></span>m <span class="_ _40"> </span>IM.  A <span class="_ _6c"> </span>i<span class="_ _0"></span>ncidência <span class="_ _6d"> </span>de <span class="_ _6d"> </span>hemorragias <span class="_ _6d"> </span>clinica<span class="_ _0"></span>mente </div><div class="t m0 x13 h27 y216 ffe fsa fc0 sc0 ls1 ws1">significativas <span class="_ _6a"></span>foi <span class="_ _6a"></span>similar <span class="_ _6a"></span>àque<span class="_ _0"></span>la <span class="_ _6a"></span>observ<span class="_ _0"></span>ada <span class="_ _6a"></span>quando <span class="_ _6a"></span>fora<span class="_ _0"></span>m <span class="_ _6a"></span>administrados <span class="_ _6a"></span>tro<span class="_ _0"></span>mbolíticos <span class="_ _6a"></span>associados <span class="_ _6a"></span>com <span class="_ _6a"></span>heparina <span class="_ _6a"></span>e <span class="_ _6c"></span>AAS<span class="_ _10"></span> </div><div class="t m0 x13 h27 y217 ffe fsa fc0 sc0 ls1 ws1">(ácido acetilsalicílico)<span class="_ _0"></span><span class="ls12">.   </span> </div><div class="t m0 x13 h24 y218 fff fsa fc0 sc0 ls1 ws1">Inibidores <span class="_ _6f"> </span>da <span class="_ _6e"> </span>glicoproteína<span class="_ _0"></span> <span class="_ _6f"> </span>IIb/IIIa <span class="_ _6e"> </span>(<span class="_ _0"></span>medicamentos <span class="_ _6e"> </span>usados <span class="_ _6f"> </span>pa<span class="_ _0"></span>ra <span class="_ _6f"> </span>inibir <span class="_ _6e"> </span>a <span class="_ _6f"> </span>coa<span class="_ _0"></span>gulação <span class="_ _6e"> </span>sanguínea):<span class="_ _0"></span><span class="ffe"> <span class="_ _6e"> </span>como <span class="_ _6f"> </span>há <span class="_ _6e"> </span>a </span></div><div class="t m0 x13 h27 y219 ffe fsa fc0 sc0 ls1 ws1">possibilidade de interação <span class="_ _6"></span>entre clopidogrel e os <span class="_ _7"></span>inibid<span class="_ _0"></span>ores da <span class="_ _6"></span>glicoproteína IIb/IIIa, a <span class="_ _6"></span>utilização em <span class="_ _7"></span>as<span class="_ _0"></span>sociação desses <span class="_ _6"></span>dois </div><div class="t m0 x13 h27 y21a ffe fsa fc0 sc0 ls1 ws1">produtos deve ser feita co<span class="_ _0"></span>m cautela. <span class="_ _0"></span> </div><div class="t m0 x13 h24 y21b fff fsa fc0 sc0 ls1 ws1">Anticoagulantes injetáveis (c<span class="_ _6"></span>omo <span class="_ _6"></span>por <span class="_ _6"></span>exemplo, <span class="_ _6"></span>a <span class="_ _6"></span>heparina):<span class="ffe"> c<span class="_ _6"></span>omo <span class="_ _6"></span>há <span class="_ _7"></span>uma possibilidade de <span class="_ _7"></span>interação<span class="_ _0"></span> <span class="_ _6"></span>entre <span class="_ _6"></span>o <span class="_ _7"></span>clop<span class="_ _0"></span>idogrel </span></div><div class="t m0 x13 h27 y21c ffe fsa fc0 sc0 ls1 ws1">e a heparina, o uso co<span class="_ _0"></span>ncomitante necessita ser feito co<span class="_ _0"></span>m cuidad<span class="_ _0"></span>o.  <span class="_ _0"></span> </div><div class="t m0 x13 h24 y21d fff fsa fc0 sc0 ls1 ws1">Anticoagulante oral:<span class="_ _0"></span><span class="ffe"> devido <span class="_ _6"></span>ao risco <span class="_ _6"></span>aumentado de <span class="_ _6"></span>sangramento o uso <span class="_ _6"></span>em associação de <span class="_ _6"></span>varfarina <span class="_ _6"></span>e clopidogrel necessita </span></div><div class="t m0 x13 h27 y21e ffe fsa fc0 sc0 ls1 ws1">ser avaliado co<span class="_ _0"></span>m cautela.    </div><div class="t m0 x13 h24 y21f fff fsa fc0 sc0 ls1 ws1">Ácido <span class="_ _10"></span>acetilsalicílico <span class="_ _10"></span>(AAS):<span class="_ _0"></span><span class="ffe"> <span class="_ _10"></span>devido <span class="_ _10"></span>a <span class="_ _10"></span>uma <span class="_ _0"></span>p<span class="_ _0"></span>ossível <span class="_ _10"></span>interaçã<span class="_ _0"></span>o <span class="_ _10"></span>entre <span class="_ _0"></span>o<span class="_ _0"></span> <span class="_ _0"></span>clo<span class="_ _0"></span>pidogrel <span class="_ _10"></span>e <span class="_ _10"></span>o <span class="_ _10"></span>AAS, <span class="_ _0"></span>o <span class="_ _10"></span>uso <span class="_ _10"></span>em <span class="_ _0"></span>a<span class="_ _0"></span>ssociação <span class="_ _10"></span>dess<span class="_ _0"></span>es </span></div><div class="t m0 x13 h27 y220 ffe fsa fc0 sc0 ls1 ws1">dois produtos deve ser f<span class="_ _6"></span>eito com cautela. <span class="_ _6"></span>Entretanto<span class="_ _0"></span>, a associação de clopidogrel e AA<span class="_ _6"></span>S (75 <span class="ff12">–</span> 325 m<span class="_ _6"></span>g uma v<span class="_ _6"></span>ez ao dia) tem </div><div class="t m0 x13 h27 y221 ffe fsa fc0 sc0 ls1 ws1">sido feita por até u<span class="_ _0"></span>m ano.   </div><div class="t m0 x13 h24 y222 fff fsa fc0 sc0 ls1 ws1">Anti-inflamatórios não esteroidais - AINEs<span class="ffe"> <span class="_ _6"></span><span class="fff">(medicamentos que tratam <span class="_ _6"></span>as <span class="_ _6"></span>inflamações):<span class="_ _0"></span><span class="ffe"> o u<span class="_ _6"></span>so de <span class="_ _6"></span>AINEs <span class="_ _6"></span>e <span class="_ _6"></span>clopidogrel </span></span></span></div><div class="t m0 x13 h27 y223 ffe fsa fc0 sc0 ls1 ws1">em associação deve ser<span class="_ _0"></span> feito com cautela.  <span class="_ _10"></span> </div><div class="c x1b y21 w9 h7"><div class="t m0 x8 h8 y22 ff3 fs2 fc2 sc0 ls1 ws1">Página 51 de 106</div></div><div class="c x9 y23 w6 h9"><div class="t m0 x8 h8 y24 ff3 fs2 fc3 sc0 ls1 ws1">Voltar</div></div><div style="position:absolute;left:0px;top:0px;"><audio oncontextmenu="return false;" style="width:320px;height:35px;outline:none;" controls controlsList="nodownload"><source src="Audio/A051.mp3" type="audio/mpeg"></audio></div><a class="l" href="#pf2"><div class="d m1" style="border-style:none;position:absolute;left:747.679500px;bottom:1223.682000px;width:24.860000px;height:13.380000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.500000,0.000000,0.000000,1.500000,0.000000,0.000000]}'></div></div>
